IP44: Prostate Cancer: Epidemiology & Natural History
Saturday, May 16, 2026 3:30 PM to 5:30 PM · 2 hr. (America/New_York)
146A
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP44-01: Are we operating on the same patients over the past 2 decades? 20-year Trends in Radical Prostatectomy Demographics, Clinicopathology, and Outcomes from a Tertiary Academic Center and Multi-institutional Collaborative
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-02: Validation of the Cambridge, EAU, and STARCAP Prognostic Score in Predicting Biochemical Recurrence in Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy in the MRI Era
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-03: 5 year risk of post-prostatectomy radiotherapy in England: a national population level study.
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-04: Twenty-year specialty follow-up after radical prostatectomy or radiation for prostate cancer in Medicare beneficiaries
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-05: Marked International Variation in Pelvic Lymph Node Dissection (PLND) at Radical Prostatectomy: The TrueNTH Global Registry Experience
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-06: Impact of Central Biopsy Review on the Risk of Positive Surgical Margins and Biochemical Recurrence in Prostate Cancer Patients Undergoing Radical Prostatectomy
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-07: Validation of the EAU Favorable and Unfavorable Intermediate-Risk Prognostic Groups for Predicting Biochemical Recurrence After Radical Prostatectomy in Contemporary Prostate Cancer Patients: The Added Value of MRI-Features
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-08: The Role of an AI-based Model to Predict Long-Term Oncological Outcomes in Prostate Cancer Treated with Radical Prostatectomy
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-09: Development and Validation of A Novel Risk Model for 10-Year Other-Cause Mortality in Radical Prostatectomy Candidates: Implications for Patient Selection
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-10: A Weighted Scale to Identify EMBARK-like Patients at High-Risk for Progression and Mortality after Biochemical Recurrence (BCR) Who May Benefit from Early Intensified ADT
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-11: Physical Activity, Sleep, and Heart Rate Patterns Derived from Wearables and Their Association with Biochemical Recurrence in Prostate Cancer: Insights from the All of Us Research Program
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-12: Uncovering the Mental Health Toll of Erectile Dysfunction and Urinary Incontinence across the Prostate Cancer Care Continuum
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-13: Disease Presentation and Oncologic Outcomes of Early-Onset Prostate Cancer in a Contemporary Cohort
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-14: Clinical Outcomes of Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension: Results from Up To 25 Years of Follow-Up
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-15: Neighborhood Vulnerability and Geographic Hotspots of Advanced Prostate Cancer in Rhode Island
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-16: Association of Neighborhood-Level Food Environment with Prostate Cancer-Specific Mortality Among Men in Georgia
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-17: Neighborhood Food Swamps and High-Risk Prostate Cancer Among Men in Georgia
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-18: Geographic and Clinical Predictors of One-Day Discharge in Radical Prostatectomy
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-19: The impact of Race and physician’s specialty on performing work-up in patients first tested with a PSA > 4 ng/ml
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-20: State-Level Determinants of Prostate Cancer Mortality: The Role of Insurance and Public Health Investment
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-21: Financial Toxicity and Social Determinants of Health in Prostate Cancer: Prospective Evaluation in a Tertiary Center
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-22: Public Response to a Presidential Cancer Disclosure: A Google Trends Analysis of Health Information Seeking After Joe Biden’s Prostate Cancer Announcement
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-24: Exploring the association between alcohol consumption and prostate cancer risk in the BIOmarkers of Prostate Cancer/Prevention and Environment (BIOCaPPE) prospective cohort
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-25: New insights into metabolic syndrome and prostate cancer risk from the prospective BIOmarkers of Prostate Cancer/Prevention and Environment (BIOCaPPE) cohort
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-26: Specific PM2.5 Constituents, Particularly Nitrate (NO3?), are Associated with Increased Prostate Cancer Risk: A Prospective Analysis of 224,272 Men in the UK Biobank
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
Jingcheng Zhou · Peking University First Hospital
IP44-27: National Trends in Genetic Counseling and Testing Among Eligible Patients With High-Risk Prostate Cancer
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-28: Association of Androgen Deprivation Therapy With Cardiovascular and Bone-Related Adverse Events in Patients With and Without Prior History of These Events
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-29: Association between metformin use in individuals with prostate cancer and mortality: an analysis of the RADICAL-PC study
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
IP44-30: INFLUENCE OF HEREDITARY AND ENVIRONMENTAL FACTORS ON THE AGGRESSIVENESS OF PROSTATE CANCER
Saturday, May 16, 2026 3:30 PM to 5:30 PM
146A
Registered attendees
KS
Kristian Stensland
Assistant ProfessorUniversity of Michigan